CervoMed Inc. said its oral small-molecule candidate neflamapimod has been selected for inclusion in the UK EXPERTS-ALS clinical trial platform, which is designed to rapidly evaluate investigational therapies for amyotrophic lateral sclerosis. The randomized, multicenter, open-label, multi-arm study will initially enroll about 35 ALS participants for 18–24 weeks to assess changes in blood neurofilament light chain (NfL), with potential expansion to up to 80 participants and additional clinical and survival endpoints. The company said this will be the first UK-based trial to evaluate neflamapimod in ALS, with the first patient expected to be dosed by the end of 2026; no study results have been reported yet.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief on February 18, 2026, and is solely responsible for the information contained therein.